Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
PHA121 is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist. Data from Phase 1 studies in healthy volunteers demonstrate rapid exposure and predictable linear pharmacokinetics, and inhibition of bradykinin-induced hemodynamic changes in a human bradykinin-challenge study. PHVS416, a softgel capsule formulation containing PHA121, is currently in Phase 2 clinical development for the on-demand treatment of HAE.
Pharvaris was founded in October 2015 by executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Jul 30, 2021Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
Jul 09, 2021Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
Jul 01, 2021Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
More events are coming soon.